Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma (Oncogene, (2022), 41, 21, (2973-2983), 10.1038/s41388-022-02305-x)

Patience Odeniyide, Marielle E. Yohe, Kai Pollard, Angelina V. Vaseva, Ana Calizo, Lindy Zhang, Fausto J. Rodriguez, John M. Gross, Amy N. Allen, Xiaolin Wan, Romel Somwar, Karisa C. Schreck, Linda Kessler, Jiawan Wang, Christine A. Pratilas

Producción científica: Comment/debaterevisión exhaustiva

2 Citas (Scopus)

Resumen

Following the publication of this article a number of copy editing omissions were noted. These have now been corrected.

Idioma originalEnglish (US)
Páginas (desde-hasta)3037
Número de páginas1
PublicaciónOncogene
Volumen41
N.º21
DOI
EstadoPublished - may 20 2022

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Cancer Research

Huella

Profundice en los temas de investigación de 'Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma (Oncogene, (2022), 41, 21, (2973-2983), 10.1038/s41388-022-02305-x)'. En conjunto forman una huella única.

Citar esto